Global Hepatitis C Market – Industry Trends and Forecast to 2029

Market Analysis and Size

Hepatitis C is a virus that produces inflammation in the liver and, if not treated promptly, can result in serious liver damage. A patient's infected blood spreads hepatitis C. HIV/AIDS, heavy alcohol consumption, toxin exposure, and some medications can all lead to hepatitis C infection caused by a virus. Hepatic encephalopathy, easy bleeding and bruising, fatigue, poor appetite, jaundice, dark-coloured urine, itchy skin, ascites, and swallowing in legs are all symptoms of hepatitis. According to a survey study published by the "Centers for Disease Control and Prevention" in 2016, hepatitis C affected 2.4 million people in the United States.

Data Bridge Market Research analyses that the hepatitis C market was valued at USD 48.51 billion in 2021 and is expected to reach USD 134.54 billion by 2029, registering a CAGR of 13.60% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

The hepatitis C virus causes hepatitis C, a viral infection that mostly affects the liver. Cirrhosis is frequently the result, and it can lead to consequences including liver failure, malignancy, and esophageal and gastric varices. There are usually no signs at the beginning of an infection. Antiviral drugs are a type of medicine that is used to treat viral diseases such as HIV, herpes, hepatitis, and influenza. Vaccines are the most common form of administration for these medications. Furthermore, the majority of these medications are used to treat specific viral infections, but a select handful (broad-spectrum antiviral treatments) are effective against different virus forms. Antiviral medications used to treat viral infections of the liver, such as hepatitis, are known as hepatic antiviral agents.

Hepatitis C market Dynamics

Drivers

• Rise in the prevalence of hepatitis

The rising prevalence of hepatitis is a major factor driving the hepatitis C market's growth rate. According to World Health Organization (WHO) data published in July 2021, an estimated 58 million individuals have chronic hepatitis C virus infection, with 1.5 million new infections occurring each year. The hepatitis C virus is a blood-borne pathogen, and the most common way to contract it is by contact with small amounts of blood. This frequently occurs as a result of improper injections and poor health care. 

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of hepatitis C market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness about the will expand the hepatitis C market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of hepatitis C market. Along with this, rising geriatric population and surge in medical tourism will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hepatitis C market growth. In March 2021, Dicerna Pharmaceuticals and Roche began a Phase II combo trial for the treatment of chronic hepatitis infection with the experimental GalXC RNAi candidate, RG6346. As a result, market research and development activities are crucial to improve market expansion.

• Launch of new products

The launch of new products is estimated to boost the new market opportunities. Mavyret (glecaprevir and pibrentasvir) pills, for instance, were approved by the US Food and Drug Administration in April 2019 to treat six genotypes of hepatitis C virus (HCV) in children aged 12 to 17. Furthermore, in June 2021, Gilead Sciences, Inc. got FDA approval for Epclusa for the treatment of chronic hepatitis C virus (HCV) in children under the age of three, regardless of HCV genotype or severity of liver disease.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the hepatitis C market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost of the treatment will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and low awareness about hepatitis C will pose major challenges to the market’s growth rate. Additionally, the dearth of skilled professionals and strict government regulations will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This hepatitis C market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hepatitis C market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Hepatitis C market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global hepatitis C market Scope

The hepatitis C market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Acute Hepatitis C
• Chronic Hepatitis C
• Other

Treatment

• Antiviral Drugs
• Telbivudine
• Entecavir
• Tenofovir disoproxil
• Lamivudine
• Others
• Vaccine
• Immune Modulator Drugs
• Pegylated interferon
• Interferon alpha
• Surgery
• Others

Diagnosis

• Liver Biopsy
• Blood Tests
• Imaging Tests
• Ultrasound
• MRI
• CT scan
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Hepatitis C market Regional Analysis/Insights

The hepatitis C market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the hepatitis C market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the hepatitis C market because of the growing presence of major key players and the rising number of research and development activities will further propel the market’s growth rate in this region. Additionally, an increase in number of FDA approval drugs will further propel the market’s growth rate in this region. 

Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers and growing government initiatives in this region. Also, development of healthcare infrastructure will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Hepatitis C market Share Analysis

The hepatitis C market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hepatitis C market.

Some of the major players operating in the hepatitis C market are:

• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Germany)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Cadila Pharmaceuticals (India) 
• Eli Lilly and Company (U.S.)
• LEO Pharma A/S (Denmark)
• Cipla Inc. (U.S.)
• Aurobindo Pharma (India)
• Lupin (India)
• Sumitomo Corporation (Japan)

SKU-53473